Bank of America issues buy rating for Iambic Therapeutics with $30 price target
BAC Bank Of America Corp
$50.68 +0.26%
View chart & analysis → 
- 1Bank of America presents a buy rating for Iambic Therapeutics with a price target of $30, forecasting an upside potential of approximately 194%.
- 2Iambic Therapeutics will present clinical data at the 2026 ESMO showing a 36% reduction in tumor size among patients receiving intensive treatment.
- 3Iambic Therapeutics has secured over $2 billion in investments from pharmaceutical partners including Takeda, AbbVie, Bayer, and Revolution Medicines.
So what's the key point?
Bank of America is recommending the purchase of Iambic Therapeutics stock with a target price of $30. This company has already received more than $2 billion in investment from major pharmaceutical companies.
Source Proactive +2 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.